EULAR® 2024 Insights
Systemic and Connective Tissue Disease
EULAR® 2024 Insights
EULAR® 2024 Insights- Implications of Newly Established Malignancy Screening Guidelines for Idiopathic Inflammatory Myopathies: A Multicenter, International Evaluation of Clinical and Economic Impact by the Myositis Audit and Research Collaborative Group
FEATURING
Jessica Day
- 112 views
- July 24, 2024
EULAR® 2024 Insights
EULAR® 2024 Insights- Implications of Newly Established Malignancy Screening Guidelines for Idiopathic Inflammatory Myopathies: A Multicentre, International Evaluation of Clinical and Economic Impact by the Myositis Audit and Research Collaborative Group
FEATURING
Jessica Day
- 4 views
- July 24, 2024
EULAR® 2024 Insights
EULAR® 2024 Insights: Implications of Newly Established Malignancy Screening Guidelines for Idiopathic Inflammatory Myopathies: A Multicentre, International Evaluation of Clinical and Economic Impact by the Myositis Audit and Research Collaborative Group
FEATURING
Jessica Day
- 1 view
- July 24, 2024
EULAR® 2024 Insights
EULAR® 2024 Insights: Inflammatory Myopathies - Update on Therapies
FEATURING
Britta Maurer
- 9 views
- July 22, 2024
EULAR® 2024 Insights
EULAR® 2024 Insights: Sarcoidosis – (Not Just) Joint, Bone, and Muscles
FEATURING
Arthur Yee
- 8 views
- July 10, 2024